Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review-Reference-Cited by-同舟云学术

Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review

Published:2016-08-18 Issue:1 Volume:12 Page:81-88
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Zhu Xiaoli,Bai Qianming,Lu Yongming,Qi Peng,Ding Jianhui,Wang Jialei,Zhou Xiaoyan

Funder

the National Natural Science Foundation of China

Shanghai hospital development center Emerging advanced technology joint research project

Shanghai Key Developing Disciplines

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11523-016-0455-4.pdf

Reference29 articles.

1. Zhi XY, Zou XN, Hu M, Jiang Y, Jia MM, Yang GH. Increased lung cancer mortality rates in the Chinese population from 1973–1975 to 2004–2005: an adverse health effect from exposure to smoking. Cancer. 2015;121 Suppl 17:3107–12.

2. Minguet J, Smith KH, Bramlage P. Targeted therapies for treatment of non-small cell lung cancer—recent advances and future perspectives. Int J Cancer. 2016;138:2549–61.

3. Steuer CE, Ramalingam SS. Targeting EGFR in lung cancer: lessons learned and future perspectives. Mol Asp Med. 2015;45:67–73.

4. Jorge SE, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res. 2014;47:929–39.

5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2014;350:2129–39.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current management of uncommon EGFR mutations in non-small cell lung cancer;Current Problems in Cancer;2024-04

2. An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report;Journal of Medical Case Reports;2024-03-18

3. Heterogeneous distribution of EGFR mutation in NSCLC: Case report;Respiratory Medicine Case Reports;2023

4. Molecular epidemiology and clinical characteristics of epidermal growth factor receptor mutations in NSCLC: A single-center experience from India;Journal of Cancer Research and Therapeutics;2023

5. Genetic alterations shaping tumor response to anti-EGFR therapies;Drug Resistance Updates;2022-09